Several studies have reported the clinical response in HER2-positive NSCLC patients with an objective response rate (ORR) of 7.7-33% and a median progression-free survival (mPFS) of 3.2-3.7 months (11, 13). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.